From: Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
Virological response
Group A1 (n = 72)
Group A2 (n = 71)
Group B (n = 67)
Sustained virological response n.(%)
60 (83)*
53(75)â€
33 (49)
Non sustained virological response n.(%)
12 (17)
18 (25)
34 (51)‡